Safety Concerns Prompt Pause of Magrolimab Trials

Gilead paused enrollment in trials of its anti-CD47 therapy magrolimab following suspicions of a safety issue experienced by patients with acute myeloid leukemia or myelodysplastic syndrome who received it in combination with the chemotherapeutic agent azacitidine.